Oral Route of Administration Expected to Hold 53% Of Market Share for Birch Allergy Treatment Market | FMI Study

During the forecast period 2023 to 2033, the Birch allergy treatment market is expected to grow at a value of 7% CAGR, according to Future Market Insights. By the year 2033, the global market for Birch allergy treatment is expected to rise up to a market valuation of US$ 1123.24 Million.

Growth of the market can be attributed to the growing awareness of allergies and their impact on health. The increasing prevalence of allergic reactions has prompted healthcare providers to focus more on allergy prevention and treatment. As a result, more people are seeking medical treatment for their allergies, including those caused by birch pollen.

One of the most promising developments in the Birch Allergy Treatment Market is the use of immunotherapy. Immunotherapy is a treatment that involves exposing a patient to gradually increasing doses of an allergen, such as birch pollen. The idea behind this treatment is to desensitize the patient’s immune system to the allergen, which can help reduce or even eliminate allergic reactions.

Get Latest Sample Copy@ https://www.futuremarketinsights.com/reports/sample/rep-gb-16769

In addition to traditional treatment options, there has also been a growing interest in alternative therapies for the treatment of birch allergy. These therapies include acupuncture, herbal remedies, and homeopathy. While the efficacy of these treatments is still being studied, they have shown promising results in some cases and may provide additional treatment options for birch allergy sufferers.

Key Takeaways from the Market Study

• The Birch allergy treatment market is expected to grow at a value of 7% CAGR in the forecast period 2023-2033
• Oral route of administration is expected to hold 53% of the market share in 2023 for Birch allergy treatment market.

• North America is expected to possess 48% market share for Birch allergy treatment market in 2023.
• Europe Birch allergy treatment market size is expected to possess 43% market share in 2023.

“Significant increase in the number of drugs and therapies available for the treatment of birch allergy is not only increasing treatment options for patients but has also has made treatments more effective and efficient.” states an FMI analyst

Ask An Analyst @ https://www.futuremarketinsights.com/ask-question/rep-gb-16769

Competitive Landscape

Key players in the Birch allergy treatment market are Allergy Therapeutics Plc, Regeneron Pharmaceuticals Inc, Desentum, HAL Allergy Group, Roxall Medizin GmbH, Worg Pharmaceuticals AG, S-TARget therapeutics GmbH, Adamis Pharmaceuticals Corporation, Merck KGaA and Stallergenes Greer plc

• Allergy Therapeutics Plc is a biopharmaceutical company that specializes in developing immunotherapy products for the treatment of allergies, including birch allergy. The company has developed a range of products for the treatment of birch allergy, including subcutaneous and sublingual immunotherapies.
• Desentum’s product for birch allergy is called ASIT+TM Birch, which is a vaccine that combines Desentum’s proprietary peptide-based technology with an adjuvant to enhance the immune response.

More Valuable Insights

Future Market Insights, in its new offering, presents an unbiased analysis of the global Birch allergy treatment market, presenting historical analysis from 2018 to 2022 and forecast statistics for the period of 2023 to 2033.

The study reveals essential insights on the basis of Drug Class (Antihistamines, Cetirizine, Diphenhydramine, Decongestant, Pseudoephedrine, Oxymetazoline) Route of Administration (Oral, Intranasal), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) Region (North America, Latin America, Europe, South Asia, East Asia, Oceania, Middle East & Africa)

Request Discount@ https://www.futuremarketinsights.com/request-discount/rep-gb-16769

Key Segments Profiled in the Birch Allergy Treatment Market Industry Survey

Drug Class:

• Antihistamines
• Cetirizine
• Diphenhydramine
• Decongestant
• Pseudoephedrine
• Oxymetazoline

Route of Administration:

• Oral
• Intranasal

Distribution Channel:

• Hospital Pharmacy
• Online Pharmacy
• Retail Pharmacy

About FMI:

Future Market Insights (ESOMAR certified market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.

Contact Us:
Future Market Insights,
Unit No: 1602-006,
Jumeirah Bay 2,
Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers,
Dubai,
United Arab Emirates
For Sales Enquiries: sales@futuremarketinsights.com
Browse All Reports : https://www.futuremarketinsights.com/reports
LinkedIn| Twitter| Blogs